• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索促炎免疫介质:揭示溶酶体贮积病中的神经炎症机制

Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases.

作者信息

Pandey Manoj Kumar

机构信息

Cincinnati Children's Hospital Medical Center, Division of Human Genetics, Cincinnati, OH 45229-3026, USA.

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0515, USA.

出版信息

Biomedicines. 2023 Apr 1;11(4):1067. doi: 10.3390/biomedicines11041067.

DOI:10.3390/biomedicines11041067
PMID:37189685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10135900/
Abstract

Lysosomal storage diseases are a group of rare and ultra-rare genetic disorders caused by defects in specific genes that result in the accumulation of toxic substances in the lysosome. This excess accumulation of such cellular materials stimulates the activation of immune and neurological cells, leading to neuroinflammation and neurodegeneration in the central and peripheral nervous systems. Examples of lysosomal storage diseases include Gaucher, Fabry, Tay-Sachs, Sandhoff, and Wolman diseases. These diseases are characterized by the accumulation of various substrates, such as glucosylceramide, globotriaosylceramide, ganglioside GM2, sphingomyelin, ceramide, and triglycerides, in the affected cells. The resulting pro-inflammatory environment leads to the generation of pro-inflammatory cytokines, chemokines, growth factors, and several components of complement cascades, which contribute to the progressive neurodegeneration seen in these diseases. In this study, we provide an overview of the genetic defects associated with lysosomal storage diseases and their impact on the induction of neuro-immune inflammation. By understanding the underlying mechanisms behind these diseases, we aim to provide new insights into potential biomarkers and therapeutic targets for monitoring and managing the severity of these diseases. In conclusion, lysosomal storage diseases present a complex challenge for patients and clinicians, but this study offers a comprehensive overview of the impact of these diseases on the central and peripheral nervous systems and provides a foundation for further research into potential treatments.

摘要

溶酶体贮积病是一组罕见和极其罕见的遗传性疾病,由特定基因缺陷引起,导致有毒物质在溶酶体中蓄积。这种细胞物质的过度蓄积刺激免疫细胞和神经细胞的激活,导致中枢和外周神经系统的神经炎症和神经退行性变。溶酶体贮积病的例子包括戈谢病、法布里病、泰-萨克斯病、桑德霍夫病和沃尔曼病。这些疾病的特征是在受影响的细胞中蓄积各种底物,如葡糖脑苷脂、球三糖神经酰胺、神经节苷脂GM2、鞘磷脂、神经酰胺和甘油三酯。由此产生的促炎环境导致促炎细胞因子、趋化因子、生长因子和补体级联反应的几个成分的产生,这些成分促成了这些疾病中所见的进行性神经退行性变。在本研究中,我们概述了与溶酶体贮积病相关的基因缺陷及其对神经免疫炎症诱导的影响。通过了解这些疾病背后的潜在机制,我们旨在为监测和管理这些疾病的严重程度提供潜在生物标志物和治疗靶点的新见解。总之,溶酶体贮积病给患者和临床医生带来了复杂的挑战,但本研究全面概述了这些疾病对中枢和外周神经系统的影响,并为进一步研究潜在治疗方法奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4523/10135900/e45f49ce3cbf/biomedicines-11-01067-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4523/10135900/e45f49ce3cbf/biomedicines-11-01067-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4523/10135900/e45f49ce3cbf/biomedicines-11-01067-g001.jpg

相似文献

1
Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases.探索促炎免疫介质:揭示溶酶体贮积病中的神经炎症机制
Biomedicines. 2023 Apr 1;11(4):1067. doi: 10.3390/biomedicines11041067.
2
GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.GM2 神经节苷脂蓄积导致早发型泰萨二氏病小鼠模型发生神经炎症和行为改变。
J Neuroinflammation. 2020 Sep 20;17(1):277. doi: 10.1186/s12974-020-01947-6.
3
[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].[GM2神经节苷脂贮积症的分子发病机制与治疗方法]
Yakugaku Zasshi. 2013;133(2):269-74. doi: 10.1248/yakushi.12-00199.
4
Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease.颗粒蛋白前体与氨基己糖苷酶 A 结合,改善泰萨二氏症 GM2 神经节苷脂蓄积和溶酶体贮积。
J Mol Med (Berl). 2018 Dec;96(12):1359-1373. doi: 10.1007/s00109-018-1703-0. Epub 2018 Oct 20.
5
Absence of infiltrating peripheral myeloid cells in the brains of mouse models of lysosomal storage disorders.溶酶体贮积症小鼠模型脑组织中无浸润性外周髓样细胞。
J Neurochem. 2019 Mar;148(5):625-638. doi: 10.1111/jnc.14483. Epub 2018 Aug 9.
6
New Approaches to Tay-Sachs Disease Therapy.泰-萨克斯病治疗的新方法。
Front Physiol. 2018 Nov 20;9:1663. doi: 10.3389/fphys.2018.01663. eCollection 2018.
7
Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling.基因表达谱揭示的泰-萨克斯病和桑德霍夫病的分子病理生理学
Hum Mol Genet. 2002 May 15;11(11):1343-50. doi: 10.1093/hmg/11.11.1343.
8
Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses.糖脂累积的大型动物 GM2 神经节苷脂贮积症模型的自然病史研究。
PLoS One. 2020 Dec 1;15(12):e0243006. doi: 10.1371/journal.pone.0243006. eCollection 2020.
9
Plasma G ganglioside potential biomarker for diagnosis, prognosis and disease monitoring of GM2-Gangliosidosis.血浆 G 神经节苷脂可能成为 GM2 神经节苷脂贮积症的诊断、预后和疾病监测的生物标志物。
Mol Genet Metab. 2023 Feb;138(2):106983. doi: 10.1016/j.ymgme.2022.106983. Epub 2022 Dec 26.
10
Animal models of GM2 gangliosidosis: utility and limitations.GM2神经节苷脂沉积症的动物模型:效用与局限性。
Appl Clin Genet. 2016 Jul 20;9:111-20. doi: 10.2147/TACG.S85354. eCollection 2016.

引用本文的文献

1
Emerging role of complement system in the induction of neuroinflammation in adenylosuccinate lyase deficiency disorder.腺苷酸琥珀酸裂解酶缺乏症中补体系统在诱导神经炎症方面的新作用。
Brain Behav Immun Health. 2025 Aug 19;48:101091. doi: 10.1016/j.bbih.2025.101091. eCollection 2025 Oct.
2
Fabry Disease Beyond Storage: The Role of Inflammation in Disease Progression.法布里病:超越贮积现象——炎症在疾病进展中的作用
Int J Mol Sci. 2025 Jul 22;26(15):7054. doi: 10.3390/ijms26157054.
3
Molecular Diplomacy of Lipids in the War of Immunity: Bridging Rare and Common Disease Mechanisms.

本文引用的文献

1
Gene therapy for lysosomal storage diseases: Current clinical trial prospects.溶酶体贮积症的基因治疗:当前临床试验前景
Front Genet. 2023 Jan 13;14:1064924. doi: 10.3389/fgene.2023.1064924. eCollection 2023.
2
PR-957 Suppresses Th1 and Th17 Cell Differentiation via Inactivating PI3K/AKT Pathway in Alzheimer's Disease.PR-957通过使阿尔茨海默病中的PI3K/AKT信号通路失活来抑制Th1和Th17细胞分化。
Neuroscience. 2023 Feb 1;510:82-94. doi: 10.1016/j.neuroscience.2022.10.021. Epub 2022 Dec 26.
3
Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.
免疫之战中脂质的分子外交:连接罕见病与常见疾病的机制
Int J Mol Sci. 2025 Jun 10;26(12):5568. doi: 10.3390/ijms26125568.
4
Combined treatment of Ketogenic diet and propagermanium reduces neuroinflammation in Tay-Sachs disease mouse model.生酮饮食与锗联合治疗可减轻泰-萨克斯病小鼠模型中的神经炎症。
Metab Brain Dis. 2025 Feb 28;40(3):133. doi: 10.1007/s11011-025-01553-6.
5
Enzyme Replacement Therapy in Mucopolysaccharidosis Type VII: A Three-Year Clinical Outcome Study of the First Taiwanese Case.黏多糖贮积症VII型的酶替代疗法:首例台湾患者的三年临床疗效研究
Diagnostics (Basel). 2025 Feb 14;15(4):464. doi: 10.3390/diagnostics15040464.
6
Extracellular Vesicles as Tools for Crossing the Blood-Brain Barrier to Treat Lysosomal Storage Diseases.细胞外囊泡作为穿越血脑屏障治疗溶酶体贮积病的工具
Life (Basel). 2025 Jan 9;15(1):70. doi: 10.3390/life15010070.
7
Unifying biology of neurodegeneration in lysosomal storage diseases.溶酶体贮积病中神经退行性变的统一生物学机制
J Inherit Metab Dis. 2025 Jan;48(1):e12833. doi: 10.1002/jimd.12833.
8
Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms.补体系统与黏附分子在法布瑞氏病中的交锋:对发病机制和疾病机制的深入了解。
Int J Mol Sci. 2024 Nov 14;25(22):12252. doi: 10.3390/ijms252212252.
9
Gaucher disease type 3c: Expanding the clinical spectrum of an ultra-rare disease.3c型戈谢病:拓展一种超罕见疾病的临床谱
JIMD Rep. 2024 Aug 15;65(5):313-322. doi: 10.1002/jmd2.12440. eCollection 2024 Sep.
10
Examining the Role of a Functional Deficiency of Iron in Lysosomal Storage Disorders with Translational Relevance to Alzheimer's Disease.探讨铁功能缺陷在溶酶体贮积症中的作用及其对阿尔茨海默病的转化相关性。
Cells. 2023 Nov 16;12(22):2641. doi: 10.3390/cells12222641.
靶向 COVID-19 和戈谢病中的补体-鞘脂系统:一种新治疗策略的证据。
Int J Mol Sci. 2022 Nov 18;23(22):14340. doi: 10.3390/ijms232214340.
4
Gene Expression Profile in the Sandhoff Mouse Brain with Progression of Age.沙夫豪森病鼠脑内随年龄进展的基因表达谱。
Genes (Basel). 2022 Nov 3;13(11):2020. doi: 10.3390/genes13112020.
5
New insight into neurological degeneration: Inflammatory cytokines and blood-brain barrier.神经退行性变的新见解:炎性细胞因子与血脑屏障。
Front Mol Neurosci. 2022 Oct 24;15:1013933. doi: 10.3389/fnmol.2022.1013933. eCollection 2022.
6
A multifaceted evaluation of microgliosis and differential cellular dysregulation of mammalian target of rapamycin signaling in neuronopathic Gaucher disease.对神经元型戈谢病中微胶质细胞增生及雷帕霉素哺乳动物靶标信号转导的细胞差异失调的多方面评估。
Front Mol Neurosci. 2022 Sep 20;15:944883. doi: 10.3389/fnmol.2022.944883. eCollection 2022.
7
A systematic review of economic evaluations of enzyme replacement therapy in Lysosomal storage diseases.溶酶体贮积症中酶替代疗法的经济学评估系统评价。
Cost Eff Resour Alloc. 2022 Sep 19;20(1):51. doi: 10.1186/s12962-022-00369-w.
8
Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease.戈谢氏病患者外周炎症和氧化应激生物标志物的生物学变异性。
Int J Mol Sci. 2022 Aug 16;23(16):9189. doi: 10.3390/ijms23169189.
9
Pre-existing humoral immune comebacks control the development of the severe form of coronavirus disease 2019 in Gaucher patients.既往存在的体液免疫反应控制了戈谢病患者中重症2019冠状病毒病的发展。
Clin Transl Discov. 2022 Jun;2(2):e96. doi: 10.1002/ctd2.96. Epub 2022 Jun 29.
10
Identification of a novel therapeutic target underlying atypical manifestation of Gaucher disease.鉴定戈谢病非典型表现背后的新治疗靶点。
Clin Transl Med. 2022 May;12(5):e862. doi: 10.1002/ctm2.862.